Bionano Laboratories Announces New Category I CPT Code For OGM Use In Hematological Malignancy Analysis, Expected To Be Included In The Next CPT Codebook And To Be Effective January 1, 2025

Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of optical genome mapping (OGM) in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ HemeOne laboratory developed test (LDT) from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effective January 1, 2025.